Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site.
about
Evidence that a protein-protein interaction 'hot spot' on heterotrimeric G protein betagamma subunits is used for recognition of a subclass of effectorsUnderstanding molecular recognition by G protein βγ subunits on the path to pharmacological targetingChemical synthesis and X-ray structure of a heterochiral {D-protein antagonist plus vascular endothelial growth factor} protein complex by racemic crystallographyHuman iPSC-derived endothelial cell sprouting assay in synthetic hydrogel arraysSmall-molecule inhibitors of protein-protein interactions: progressing towards the dreamPeptide secondary structure modulates single-walled carbon nanotube fluorescence as a chaperone sensor for nitroaromaticsCross-strand interactions of fluorinated amino acids in β-hairpin constructs.Peptides selected to bind the Gal80 repressor are potent transcriptional activation domains in yeast.Tropism switching in Bordetella bacteriophage defines a family of diversity-generating retroelements.Phage display of random peptide libraries: applications, limits, and potential.Exploring protein-protein interactions with phage display.Novel peptide inhibitors of angiotensin-converting enzyme 2.Discovery of antagonist peptides against bacterial helicase-primase interaction in B. stearothermophilus by reverse yeast three-hybrid.Directed evolution of a biterminal bacterial display scaffold enhances the display of diverse peptidesBacterial display enables efficient and quantitative peptide affinity maturation.Peptide ligands that use a novel binding site to target both TGF-β receptors.Synthetic phage for tissue regenerationPhage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.Folding and function in α/β-peptides: targets and therapeutic applications.Design of growth factor sequestering biomaterialsClinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.Peptides with anticancer use or potential.Conversion of low-affinity peptides to high-affinity peptide binders by using a β-hairpin scaffold-assisted approach.Targeting diverse protein-protein interaction interfaces with α/β-peptides derived from the Z-domain scaffold.Mechanistic diversity of cytokine receptor signaling across cell membranes.In vitro selection technologies to enhance biomaterial functionality.Protein catalyzed capture agents with tailored performance for in vitro and in vivo applications.Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer.Improving the Binding Affinity of in-Vitro-Evolved Cyclic Peptides by Inserting Atoms into the Macrocycle Backbone.Enhancing peptide ligand binding to vascular endothelial growth factor by covalent bond formation.Biophysical Studies of the Induced Dimerization of Human VEGF Receptor 1 Binding Domain by Divalent Metals Competing with VEGF-A.Peptide-based molecules in angiogenesis.Inhibition of caspase-9 by stabilized peptides targeting the dimerization interface.Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.Bevacizumab in the management of solid tumors.Template-induced macrocycle diversity through large ring-forming alkylations of tryptophan.G protein βγ subunits: central mediators of G protein-coupled receptor signaling.G protein betagamma subunits as targets for small molecule therapeutic development.Pseudo-active sites of protease domains: HGF/Met and Sonic hedgehog signaling in cancer.Neuropilin signalling in angiogenesis.
P2860
Q24545591-56FF6307-8AF7-4122-BD64-92373E61CFB8Q24635233-E3ACC6B8-F86A-4E6D-B29F-26C0E53D2E04Q27671712-DE69CE18-BCEC-4988-BE1D-1449CA28A8A4Q28397986-2F0EF4BA-BCE8-4A01-835A-BF16C6830D6EQ29617758-840A07D2-46E5-42C7-8F8A-79D2D23F245BQ30500522-B504A80F-11B0-4C9B-A3DF-84B930CAF3C0Q30573961-D592A0EB-DB44-41FA-844E-23FC9FC8A997Q30870486-37E43EAB-2D5D-43D3-9416-CF28066B3564Q30961710-D9E61F9D-BB0E-4287-A0E7-67AF722FBFE3Q31039269-0E69FF60-1656-45C1-9859-2003A27829E9Q31123976-47B0B86F-60CC-4001-9C80-0EE1E848082AQ31133376-A331111E-74A2-4A1A-A3D6-5BF221700247Q33215674-DCE7F76E-0174-4A80-8826-832483D60192Q33334749-48F6AC1C-7F77-474F-A09E-D37204EDF9C7Q33515720-314CB7C7-704B-4F65-8F48-20FDCE7A9E70Q33708971-5ACFD03C-0FA9-48F6-ACC1-26CC91570482Q33758770-501B9043-E555-455C-8D76-223124C44083Q34273411-C6F55C7F-0830-44BB-BA3E-FF3D6F3D8751Q34483276-73556B8F-2D4E-4592-979A-7CE29A91B12AQ34543371-3BD16EA3-B2BF-4EE9-B713-71E49A12FBD5Q34608643-0B17CE3B-8348-42BF-BB50-F5A5F2277438Q35167010-8DCD8DFE-2D44-4600-B279-121FFF3FC09AQ35394378-3947BB2A-6C53-422D-A1A4-72F7CAD1FF90Q35484964-0F433BD9-7CDA-45CA-9423-AD6CC447E90AQ35764259-948CDD2E-41AC-4D02-8744-FB6375359CB8Q36020230-7F1F4480-BC67-4220-97D0-34469073A974Q36107567-6F3A494F-D913-43B7-884B-AF4D82D408D9Q36187034-35D7C44D-A039-47A2-A4E0-0C86423854CEQ36197974-F68785D4-C249-474E-9978-2DE9601DF4B9Q36201014-F0BEE389-797A-4933-AAB6-85D74A71AA71Q36220022-48362C5F-5223-4382-8AA9-A61EE7156EA1Q36402580-DF74C287-B707-4419-929B-2D0050787D1BQ36529717-CB6B1BFB-1FFC-4F94-B8F3-78DD274AD56CQ36764907-B5223A93-BF42-4050-9D33-40CE5FA2C900Q36788459-4FC5ECDF-4824-4DC9-A390-2B7AF01FC1EBQ37104315-6CC53914-C3F3-466B-9DC5-B67D80C3095AQ37167274-A016DF63-1393-41DF-A475-0EED5D39FDE7Q37184794-D2B95E40-4A1B-47D7-9B53-C29F88D3F6BFQ37763945-7730BD1D-7A6F-4026-B4E5-E268574B81B0Q37977161-9E0E742A-4929-4DBF-9595-8890800ABDE5
P2860
Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site.
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Novel peptides selected to bin ...... get the receptor-binding site.
@ast
Novel peptides selected to bin ...... get the receptor-binding site.
@en
type
label
Novel peptides selected to bin ...... get the receptor-binding site.
@ast
Novel peptides selected to bin ...... get the receptor-binding site.
@en
prefLabel
Novel peptides selected to bin ...... get the receptor-binding site.
@ast
Novel peptides selected to bin ...... get the receptor-binding site.
@en
P2093
P356
P1433
P1476
Novel peptides selected to bin ...... get the receptor-binding site.
@en
P2093
Christinger HW
Cochran AG
Cunningham BC
Fairbrother WJ
Shriver SK
P304
17754-17764
P356
10.1021/BI981931E
P407
P577
1998-12-01T00:00:00Z